new bipolar medicationIt is well known that some people with bipolar disorder experience a variety of neuro-cognitive deficits (problems in areas such as attention, learning, and memory) in addition to their emotional and behavioral symptoms.

Because many of the medications used to treat bipolar disorder can cause cognitive problems as a side effect, psychiatrists have often debated whether these problems with learning and thinking are due to medications or are related to the underlying brain changes found in bipolar disorder. It seems likely that both factors are at play.

Some ongoing studies are looking at a medication called galantamine (Razadyne is the trade name), which is FDA approved for treating the cognitive deficits in Alzheimer’s disease. An open label study published in 2009 in the journal CNS Neuroscience Therapeutics suggested that this medication could in fact improve function in areas of attention and specific memory tasks, and the researchers reported positive changes on brain scans:

RESULTS: Compared to healthy volunteers, bipolar subjects had higher baseline subjective cognitive deficits and lower scores on objective tests of attention (Conner’s CPT) and verbal episodic memory (CVLT). After treatment, bipolar subjects experienced significant improvement of subjective cognitive scores and on objective tests of attention (Conner’s CPT) and verbal episodic memory (CVLT). In the left hippocampus NAA increased and choline (Cho) decreased in bipolar subjects during treatment.

NIMH is recruiting subjects now for a more rigorous study of this medication in people with bipolar disorder. See “Efficacy and Safety of Galantamine for Improving Dysfunction in People with Bipolar Disorder.”

The current findings are preliminary and do not suggest that we should start routinely using this medication in people with bipolar disorder. We have some concerns – one being that people diagnosed with bipolar disorder already take many medications – adding another one that has not been well tested yet could make things worse instead of better.

Also, the improvements in cognitive function overall in medications for Alzheimer’s are not thought to be robust, so we need to see that this medicine results in clinically significant improvements before we use it in our patients. Scientific significance isn’t always the same as clinically significance; a change in a lab result doesn’t always translate into meaningful changes in real life.

At this point, the research is something to follow but not necessarily act on. We need further studies that show stronger evidence that galantamine would be valuable tool for people with bipolar.

Photo by Lucy Reynell, available under a Creative Commons attribution, non-commercial license.

 







    Last reviewed: 7 Dec 2010

APA Reference
Fink, C. (2010). Galantamine as Potential Treatment for Cognitive Deficits in Bipolar Disorder. Psych Central. Retrieved on October 25, 2014, from http://blogs.psychcentral.com/bipolar/2010/12/galantamine-bipolar-disorder/

 

Bipolar Beat


Subscribe to this Blog:
Feed

Bipolar
Disorder



Archives





Candida Fink, M.D. and Joe Kraynak are authors of
Bipolar Disorder for Dummies.


Best of the Web - Blog 2008

Subscribe to this Blog: Feed

Recent Comments
  • B: Absolutely. Trouble is, the Pharma companies probably own shares in the food companies we purchase from when the...
  • B: Like many contributors to this discussion, I thought I was very much alone in this weight gain. I gained about 15...
  • candice: I take lexapro 10mg once a day. I have been diagnosed with major depressive disorder with psychotic...
  • Victoria: Hello Jil – what you wrote resonates so true with me. I grew up in constant fear because Mum was...
  • J Whitehead: Very interesting. I have been diagnosed at one time with histrionic personality disorder as well as...
Find a Therapist
Enter ZIP or postal code



Users Online: 12240
Join Us Now!